Skip to main content
Top
Published in: Journal of Immigrant and Minority Health 4/2017

01-08-2017 | Original Paper

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment

Authors: L. Nosotti, A. Petrelli, D. Genovese, S. Catone, C. Argentini, S. Vella, A. Rossi, G. Costanzo, A. Fortino, L. Chessa, L. Miglioresi, C. Mirisola

Published in: Journal of Immigrant and Minority Health | Issue 4/2017

Login to get access

Abstract

Aims of the study are to investigate, in a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome. 365 patients with HCV infection were observed between 2013 and 2014. Demographic, virological, biochemical, and genetic characteristics of each patient were investigated. Liver fibrosis was assessed by transient elastometry. Mean age of the patients (72.9 % males, 27.1 % females) is 50 years. 91.5 % % of patients are Caucasian, 8.5 % African. In the patients with HCV1 and HCV4 a higher frequency of IL28B CT is observed with a prevalence of 52.1 and 61.8 % respectively. As regards ethnic group, African people have a prevalence of 35.5 % for CC, while Caucasians have a prevalence of 23.8 % for CC. In our cohort, IL28B polymorphism does not show significant differences among ethnic groups and in HCV1 and HCV4 genotypes. As described in literature, IL28B CC genotype is confirmed as predictor of sustained virological response in both Caucasians and Africans. A significant correlation between liver fibrosis and IL28B polymorphism emerges.
Literature
2.
go back to reference Thompson AJ, Muir A, Sulkowski M, Ge D, Fellay J, Shianna KV, Urban T, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120–9.CrossRefPubMed Thompson AJ, Muir A, Sulkowski M, Ge D, Fellay J, Shianna KV, Urban T, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120–9.CrossRefPubMed
3.
go back to reference Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, Mc Hutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.CrossRefPubMedPubMedCentral Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, Mc Hutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.CrossRefPubMedPubMedCentral
4.
go back to reference Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed
5.
go back to reference Suppiah V, Maldovam M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL 28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRefPubMed Suppiah V, Maldovam M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL 28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRefPubMed
6.
go back to reference Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakmoto N, Nakagawa M, Korenaga M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.CrossRefPubMed Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakmoto N, Nakagawa M, Korenaga M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.CrossRefPubMed
7.
go back to reference Asselah T, De Muynck S, Broet P, Masliah-Planchon J, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56:527–32.CrossRefPubMed Asselah T, De Muynck S, Broet P, Masliah-Planchon J, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56:527–32.CrossRefPubMed
8.
go back to reference Mangia A, Mottola L, Santoro R. Interleukin 28B plymorphisms as predictor of response in hepatitis C genotype 2 and 3 infected patients. World J Gastroenterol. 2013;19(47):8924–8.CrossRefPubMedPubMedCentral Mangia A, Mottola L, Santoro R. Interleukin 28B plymorphisms as predictor of response in hepatitis C genotype 2 and 3 infected patients. World J Gastroenterol. 2013;19(47):8924–8.CrossRefPubMedPubMedCentral
9.
go back to reference Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.CrossRefPubMed
10.
go back to reference Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011;31:45–52.CrossRefPubMed Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011;31:45–52.CrossRefPubMed
11.
go back to reference Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772–80.CrossRefPubMed Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772–80.CrossRefPubMed
12.
go back to reference Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, Mc Hutchison JG. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–7.CrossRefPubMed Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, Mc Hutchison JG. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–7.CrossRefPubMed
13.
go back to reference Mc Carthy JJ, Li JH, Thompson A, Suchindran S, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.CrossRef Mc Carthy JJ, Li JH, Thompson A, Suchindran S, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.CrossRef
14.
go back to reference Eslam M, Leung R, Romero-Gomez M et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Eslam M, Leung R, Romero-Gomez M et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
15.
go back to reference Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver Int. 2015;35(2):482–8. doi:10.1111/liv.12630.CrossRefPubMed Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver Int. 2015;35(2):482–8. doi:10.​1111/​liv.​12630.CrossRefPubMed
16.
go back to reference Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed
17.
go back to reference Barreiro P, Pineda JA, Rallon N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis. 2011;203:1629–36.CrossRefPubMed Barreiro P, Pineda JA, Rallon N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis. 2011;203:1629–36.CrossRefPubMed
18.
go back to reference Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384–94.CrossRefPubMed Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384–94.CrossRefPubMed
20.
go back to reference Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.CrossRefPubMed Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.CrossRefPubMed
21.
go back to reference Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54(4):1127–34. doi:10.1002/hep.24503 Epub 2011 Aug 19.CrossRefPubMed Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54(4):1127–34. doi:10.​1002/​hep.​24503 Epub 2011 Aug 19.CrossRefPubMed
22.
go back to reference Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548–57.CrossRefPubMedPubMedCentral Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548–57.CrossRefPubMedPubMedCentral
23.
go back to reference Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76:327–32.CrossRefPubMed Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76:327–32.CrossRefPubMed
24.
go back to reference Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14(Suppl 5):S2. doi:10.1186/1471-2334-14-S5-S2.CrossRefPubMedPubMedCentral Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14(Suppl 5):S2. doi:10.​1186/​1471-2334-14-S5-S2.CrossRefPubMedPubMedCentral
26.
go back to reference Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–46. doi:10.1016/j.jhep.2014.07.022.CrossRefPubMed Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–46. doi:10.​1016/​j.​jhep.​2014.​07.​022.CrossRefPubMed
27.
36.
go back to reference Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29. doi:10.1002/hep.26641.CrossRefPubMedPubMedCentral Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29. doi:10.​1002/​hep.​26641.CrossRefPubMedPubMedCentral
Metadata
Title
Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment
Authors
L. Nosotti
A. Petrelli
D. Genovese
S. Catone
C. Argentini
S. Vella
A. Rossi
G. Costanzo
A. Fortino
L. Chessa
L. Miglioresi
C. Mirisola
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Immigrant and Minority Health / Issue 4/2017
Print ISSN: 1557-1912
Electronic ISSN: 1557-1920
DOI
https://doi.org/10.1007/s10903-016-0444-9

Other articles of this Issue 4/2017

Journal of Immigrant and Minority Health 4/2017 Go to the issue